Skip to main content
Caplight Logo









AMLo Biosciences

AMLo Biosciences

Private
Newcastle upon TyneHealthcare & Life Scienceshttps://amlo-biosciences.com/

Last Round

VC Round

Nov 28, 2022

Total Funding Raised

$5.2M

Company Overview

AMLo Biosciences is a biotechnology company that develops prognostic tests for the early detection of skin cancers with metastatic potential.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

prognostic testmelanoma prognostic testearly-stage melanomaskin cancer diagnosticsbiomarker testingpatient stratificationmedtechprotein biomarkerscancer Dximmunohistochemical assayIHC testmedical devicecutaneous squamous cell carcinomacSCCoropharyngeal squamous cell carcinomaOPSCC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AMLo Biosciences Comparables

Compare AMLo Biosciences with similar companies based on industry and business-model similarity.

AMLo Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SkylineDx
81%
Castle Biosciences, Inc.
75%
Myriad Genetics
68%

AMLo Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundNov 28, 2022
Series AApr 20, 2022
SeedNov 23, 2020
SeedOct 11, 2018

AMLo Biosciences Investors

Notable investors and investment history

AMLo Biosciences investors
InvestorRounds
Ascension VenturesSeries A
Future Planet Capital RegionalSeries A
Milltrust VenturesSeries A
EsperanteSeries A, Seed, VC Round
Northstar VenturesSeries A, Seed, VC Round
Milltrust International GroupSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 28, 2022

    $1.93M raised in a VC Round.

  • Apr 20, 2022

    $3.2M round completed.

AMLo Biosciences Filings

Explore SEC and related filing metadata, where available.

AMLo Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AMLo Biosciences's valuation, stock price, and market status.

Is AMLo Biosciences a public or private company?

AMLo Biosciences is a private company.

What is the current stock price of AMLo Biosciences?

AMLo Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is AMLo Biosciences worth (valuation)?

Valuation information for AMLo Biosciences is not publicly available.

Can I buy AMLo Biosciences stock?

AMLo Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AMLo Biosciences's last funding round?

AMLo Biosciences's most recent funding round was VC Round on November 28, 2022.

Who are the main investors in AMLo Biosciences?

Key investors in AMLo Biosciences include Esperante, Northstar Ventures.

Will AMLo Biosciences IPO soon?

No public IPO plans have been announced for AMLo Biosciences.

How can I track AMLo Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AMLo Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNewcastle upon Tyne
Year Founded2017
Last FundingNov 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?